SeaStar Medical Holding Corporation (ICU) presented promising real-world data from its QUELIMMUNE SAVE Registry at the AKI & CRRT 2026 conference, highlighting the effectiveness of its Selective Cytopheretic Device therapy in treating critically ill pediatric patients with acute kidney injury (AKI) and sepsis. The data showed a notable 76% survival rate at Day 28 and Day 60, and a 71% rate at Day 90, indicating a potential 50% reduction in mortality compared to historical benchmarks. Importantly, no device-related adverse events were reported among the first 21 patients treated.
This development is significant for the healthcare sector, particularly in the pediatric nephrology space, as it addresses a critical need for effective AKI treatments. SeaStar’s innovative therapy not only demonstrates a strong safety profile but also offers a new approach to modulating the immune response, which could be pivotal in preventing organ failure.
For market professionals, the stock’s recent performance—closing at $3.62, a 32.12% increase—reflects growing investor confidence in SeaStar’s potential. The ongoing NEUTRALIZE-AKI trial in adults further underscores the company’s commitment to expanding its impact in a market with substantial unmet needs.
Source: nasdaq.com